Wagner KM - Search Results

1

Randomized, double-blind, phase 1a single-ascending dose and food effect studies assessing safety and pharmacokinetics of EC5026 in healthy volunteers.

Schmidt WK, Cortés-Puch I, McReynolds CB, Croston GE, Hwang SH, Yang J, Pedersen TL, Wagner KM, Pham TT, Hunt T, Hammock BD. Schmidt WK, et al. Among authors: wagner km. Clin Transl Sci. 2024 Sep;17(9):e70033. doi: 10.1111/cts.70033. Clin Transl Sci. 2024. PMID: 39300734 Free PMC article. Clinical Trial.

2

Soluble epoxide hydrolase as a therapeutic target for pain, inflammatory and neurodegenerative diseases.

Wagner KM, McReynolds CB, Schmidt WK, Hammock BD. Wagner KM, et al. Pharmacol Ther. 2017 Dec;180:62-76. doi: 10.1016/j.pharmthera.2017.06.006. Epub 2017 Jun 19. Pharmacol Ther. 2017. PMID: 28642117 Free PMC article. Review.

3

Movement to the Clinic of Soluble Epoxide Hydrolase Inhibitor EC5026 as an Analgesic for Neuropathic Pain and for Use as a Nonaddictive Opioid Alternative.

Hammock BD, McReynolds CB, Wagner K, Buckpitt A, Cortes-Puch I, Croston G, Lee KSS, Yang J, Schmidt WK, Hwang SH. Hammock BD, et al. J Med Chem. 2021 Feb 25;64(4):1856-1872. doi: 10.1021/acs.jmedchem.0c01886. Epub 2021 Feb 7. J Med Chem. 2021. PMID: 33550801 Free PMC article.

4

Epoxygenated fatty acids and soluble epoxide hydrolase inhibition: novel mediators of pain reduction.

Wagner K, Inceoglu B, Gill SS, Hammock BD. Wagner K, et al. J Agric Food Chem. 2011 Apr 13;59(7):2816-24. doi: 10.1021/jf102559q. Epub 2010 Oct 19. J Agric Food Chem. 2011. PMID: 20958046 Free PMC article.

5

Synthesis and structure-activity relationship studies of urea-containing pyrazoles as dual inhibitors of cyclooxygenase-2 and soluble epoxide hydrolase.

Hwang SH, Wagner KM, Morisseau C, Liu JY, Dong H, Wecksler AT, Hammock BD. Hwang SH, et al. Among authors: wagner km. J Med Chem. 2011 Apr 28;54(8):3037-50. doi: 10.1021/jm2001376. Epub 2011 Apr 5. J Med Chem. 2011. PMID: 21434686 Free PMC article.

6

Comparative efficacy of 3 soluble epoxide hydrolase inhibitors in rat neuropathic and inflammatory pain models.

Wagner K, Inceoglu B, Dong H, Yang J, Hwang SH, Jones P, Morisseau C, Hammock BD. Wagner K, et al. Eur J Pharmacol. 2013 Jan 30;700(1-3):93-101. doi: 10.1016/j.ejphar.2012.12.015. Epub 2012 Dec 28. Eur J Pharmacol. 2013. PMID: 23276668 Free PMC article.

7

Soluble epoxide hydrolase inhibition is antinociceptive in a mouse model of diabetic neuropathy.

Wagner K, Yang J, Inceoglu B, Hammock BD. Wagner K, et al. J Pain. 2014 Sep;15(9):907-14. doi: 10.1016/j.jpain.2014.05.008. Epub 2014 Jun 9. J Pain. 2014. PMID: 24924124 Free PMC article.

8

Development of multitarget agents possessing soluble epoxide hydrolase inhibitory activity.

Hiesinger K, Wagner KM, Hammock BD, Proschak E, Hwang SH. Hiesinger K, et al. Among authors: wagner km. Prostaglandins Other Lipid Mediat. 2019 Feb;140:31-39. doi: 10.1016/j.prostaglandins.2018.12.003. Epub 2018 Dec 26. Prostaglandins Other Lipid Mediat. 2019. PMID: 30593866 Free PMC article. Review.

9

Pharmaceutical Effects of Inhibiting the Soluble Epoxide Hydrolase in Canine Osteoarthritis.

McReynolds CB, Hwang SH, Yang J, Wan D, Wagner K, Morisseau C, Li D, Schmidt WK, Hammock BD. McReynolds CB, et al. Front Pharmacol. 2019 May 31;10:533. doi: 10.3389/fphar.2019.00533. eCollection 2019. Front Pharmacol. 2019. PMID: 31214021 Free PMC article.

10

Soluble Epoxide Hydrolase Regulation of Lipid Mediators Limits Pain.

Wagner KM, Gomes A, McReynolds CB, Hammock BD. Wagner KM, et al. Neurotherapeutics. 2020 Jul;17(3):900-916. doi: 10.1007/s13311-020-00916-4. Neurotherapeutics. 2020. PMID: 32875445 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

88 results

Search Page

Filters